Core-binding Factor Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Core-binding Factor Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) [Phase 2]
Phase 2 MyeloMATCH trial evaluating adding venetoclax or gemtuzumab ozogamicin to the 7+3 regimen for core-binding factor acute myeloid leuk…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML [Phase 4]
Phase 4 trial comparing fludarabine plus cytarabine versus high-dose cytarabine in core-binding factor acute myeloid leukemia has completed.
-
CLINICAL_TRIALS research · 2024-08-22Clinical Trial Update: Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation [Phase 2]
This notice describes a Phase 2 clinical trial evaluating avapritinib for relapsed or refractory pediatric core-binding factor acute myeloid…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Avapritinib in CBF-AML With KIT Mutations [Phase 2]
Phase 2 clinical trial update for Avapritinib in Core Binding Factor Acute Myeloid Leukemia with KIT mutations.
-
CLINICAL_TRIALS trial_result · 2022-06-03Clinical Trial Update: Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML [Phase 2]
Phase 2 clinical trial evaluating the combination of sorafenib with standard therapy in newly diagnosed adult Core Binding Factor Acute Myel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2018-04-19Clinical Trial Update: Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia [Phase 1]
A Phase 1 study of dasatinib in combination with chemotherapy for relapsed or refractory core-binding factor acute myeloid leukemia has been…
-
CLINICAL_TRIALS trial_result · 2014-08-12Clinical Trial Update: Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 clinical trial assessing combination chemotherapy with dasatinib for newly diagnosed acute myeloid leukemia; completed with results …